CD40 antibody | LOB7/6
Mouse anti Human CD40:StarBright Violet 440
- Product Type
- Monoclonal Antibody
- Clone
- LOB7/6
- Isotype
- IgG2a
- Specificity
- CD40
Antibody Quality and Performance Guarantee
Phycoerythrin conjugated Mouse anti Human CD40 antibody, clone LOB7/6 (MCA1590PE) used to evaluate CD40 expression on PBMC by flow cytometry.
Image caption
Accessory Cells Are Activated by iRBCs PBMCs from ten malaria-naïve donors were cultured with live iRBCs or E. coli LPS for 24 h or left unstimulated. Surface expression of HLA-DR, CD40, and CD80 on accessory cells was analysed by flow cytometry. Accessory cells were defined as HLA-DR+ CD11c+ cells (A, left), and CD14+ monocytes and CD14− mDCs were selected for further analysis (A, right). Representative examples of surface expression levels of CD40, HLA-DR, and CD80 on HLA-DR+ CD11c+ CD14+ monocytes (B) and HLA-DR+ CD11c+ CD14− mDCs (C) are shown. Data are based on the collection of 100,000 total events. Results for all ten donors are summarised in (D). *, p <0.05; **, p <0.01; ***, p <0.001; p-values are for paired t tests comparing stimulated and unstimulated cells from the same donor.
From: Newman KC, Korbel DS, Hafalla JC, Riley EM.
Cross-talk with myeloid accessory cells regulates human natural killer cell interferon-gamma responses to malaria.
PLoS Pathog. 2006 Dec;2(12):e118.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
Mouse anti Human CD40 antibody, clone LOB7/6 (MCA1590) used to evaluate CD40 expression on dendritic cells by flow cytometry.
Image caption
Effect of rapamycin (Rapa) on the phenotype and function of H1-DC. DCs were either untreated, matured in response to the maturation cocktail or treated with Rapa for 3 days prior to maturation. (a) H1-DC stained for the expression of the maturation marker CD83, the costimulatory molecules CD86 and CD40, as well as the inhibitory receptor PD-L1. Dead cells were excluded from analysis using 7-AAD. Open histograms represent the level of background staining using appropriate isotype-matched controls. Data from one of 3 independent experiments are shown. (b) Phenotypic analysis of control populations of moDC treated and stained in parallel with rapamycin. (c) Effect of rapamycin on the allostimulatory capacity of DC in the allogeneic MLR. DCs were mitotically-inactivated using mitomycin C and plated in triplicate at a top dose of 104 cells per well of a 96-well round-bottomed plate; naïve CD4+ T cells were plated at 5 × 104 cells/well. Cells were incubated for 5 days before pulsing with 3H-thymidine overnight. Graphs show the mean of triplicate cultures ± S.D. Data are shown from one experiment, representative of 3 independent experiments.
From: Silk KM, Leishman AJ, Nishimoto KP, Reddy A, Fairchild PJ.
Rapamycin conditioning of dendritic cells differentiated from human ES cells promotes a tolerogenic phenotype.
J Biomed Biotechnol. 2012;2012:172420.
doi: 10.1155/2012/172420
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
FITC conjugated Mouse anti Human CD40 antibody, clone LOB7/6 (MCA1590F) used to evaluate CD40 expression on dendritic cells by flow cytometry.
Image caption
LEF-M interferes with DC differentiation. (a) Monocytes were cultured for 5 days with granulocyte–macrophage colony-stimulating factor (GM-CSF; 50 ng/ml) plus IL-4 (10 ng/ml) in the absence or presence of 150 μmol/l of the active metabolite of leflunomide (LEF-M). Subsequently, surface marker expression was determined using fluorescence-activated cell sorting (FACS) analysis. Open profiles with dotted line represent staining pattern with an isotype control antibody, open profiles with fine line indicate the staining pattern of differentiated control dendritic cells (DCs) stained with the indicated mAbs, whereas solid grey profiles show staining of DCs differentiated in the presence of LEF-M. (b) Myeloid precursor cells differentiated in the presence of LEF-M are resistant to maturation. Cells were treated as described above and then stimulated with lipopolysaccharide (LPS; 100 ng/ml) for 48 hours. Open profiles with dotted line represent staining pattern with an isotype control antibody, open profiles with fine line indicate staining of activated control DCs, and solid grey profiles show staining of DCs differentiated in the presence of LEF-M and subsequently exposed to LPS. Data are representative of at least four independent experiments. (c,d) The effects of LEF-M on DC differentiation are independent of pyrimidine depletion. The respective change in mean flourescence intensity (MFI) are shown (c) after the differentiation phase for CD40 and CD1a and (d) after subsequent maturation with 100 ng/ml LPS for CD40 and CD83 with and without 50 μmol/l uridine. White bars represent control DCs, and black bars indicate LEF-M-treated cells. Shown are mean percentage control responses ± standard error of the mean, calculated from five to eight independent experiments. Student's t-tests were calculated for control versus LEF-M-treated DCs and for LEF-M-treated DCs versus without uridine addition, as indicated. *P <0.05, **P <0.01.
From: Kirsch BM, Zeyda M, Stuhlmeier K, Grisar J, Smolen JS, Watschinger B, Stulnig TM, Hörl WH, Zlabinger GJ, Säemann MD.
The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function.
Arthritis Res Ther. 2005;7(3):R694-703.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
FITC conjugated Mouse anti Human CD40 antibody, clone LOB7/6 (MCA1590F) used to evaluate CD40 expression on dendritic cells by flow cytometry.
Image caption
Treatment with LEF-M during maturation of immature DCs leads to a differentially affected phenotype. Monocytes were cultured for 5 days with granulocyte–macrophage colony-stimulating factor (GM-CSF; 50 ng/ml) plus IL-4 (10 ng/ml). (a) On day 5 these immature dendritic cells (DCs; 5 × 105/ml) were activated with lipopolysaccharide (LPS; 100 ng/ml) in the absence or presence of 150 μmol/l of the active metabolite of leflunomide (LEF-M) for 48 hours. Surface marker expression was determined by fluorescence-activated cell sorting analysis. Open profiles with dotted line represent the staining pattern with an isotype control, open profiles with fine line indicate the staining pattern of DC exposed to LPS with the indicated monoclonal antibodies, and solid grey profiles show staining of DCs matured in the presence of LEF-M. The results shown are representative of five independent experiments. (b,c) Effect of LEF-M on maturation-associated clustering of DCs; immature DCs were stimulated with LPS in the (panel b) absence or (panel c) presence of 150 μmol/l LEF-M. After 8 hours of cultivation, cells were analyzed by inspecting photomicrographs obtained by light microscopy. Similar results were obtained in four additional experiments. MHC, major histocompatibility complex.
From: Kirsch BM, Zeyda M, Stuhlmeier K, Grisar J, Smolen JS, Watschinger B, Stulnig TM, Hörl WH, Zlabinger GJ, Säemann MD.
The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function.
Arthritis Res Ther. 2005;7(3):R694-703.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
Mouse anti Human CD40 antibody, clone LOB7/6 (MCA1590) used to evaluate CD40 expression on dendritic cells by flow cytometry.
Image caption
Effect of rapamycin (Rapa) on the phenotype and function of H1-DC. DCs were either untreated, matured in response to the maturation cocktail or treated with Rapa for 3 days prior to maturation. (a) H1-DC stained for the expression of the maturation marker CD83, the costimulatory molecules CD86 and CD40, as well as the inhibitory receptor PD-L1. Dead cells were excluded from analysis using 7-AAD. Open histograms represent the level of background staining using appropriate isotype-matched controls. Data from one of 3 independent experiments are shown. (b) Phenotypic analysis of control populations of moDC treated and stained in parallel with rapamycin. (c) Effect of rapamycin on the allostimulatory capacity of DC in the allogeneic MLR. DCs were mitotically-inactivated using mitomycin C and plated in triplicate at a top dose of 104 cells per well of a 96-well round-bottomed plate; naïve CD4+ T cells were plated at 5 × 104 cells/well. Cells were incubated for 5 days before pulsing with 3H-thymidine overnight. Graphs show the mean of triplicate cultures ± S.D. Data are shown from one experiment, representative of 3 independent experiments.
From: Silk KM, Leishman AJ, Nishimoto KP, Reddy A, Fairchild PJ.
Rapamycin conditioning of dendritic cells differentiated from human ES cells promotes a tolerogenic phenotype.
J Biomed Biotechnol. 2012;2012:172420.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
Figure B. FITC conjugated Mouse anti Human CD19 antibody, clone LT19 (MCA1940F) and RPE conjugated mouse anti human CD40 antibody, clone LOB7/6 (MCA1590PE). All experiments performed on red cell lysed Human peripheral blood gated on lymphocytes in the presence of Human SeroBlock (BUF070A).
Mouse anti Human CD40 antibody, clone LOB7/6 (MCA1590) used for the evaluation of CD40 expression on cell populations by flow cytometry.
Image caption:
DC differentiation from H1 hESC.
Cells were harvested from cultures at various time points and analysed by flow cytometry for the onset of hematopoiesis and the appearance of DC. (e) Phenotype of immature and mature H1-DCs compared with human moDC. DCs were cultured either in medium alone or medium supplemented with the maturation cocktail and stained for MHC class II, the maturation marker CD83 and classical costimulatory molecules. Dead cells were excluded from the analysis using 7-AAD. Dashed histograms show the phenotype of immature DCs while the filled histograms represent mature DCs. Open histograms depict background staining using isotype-matched controls.
From: Silk KM, Leishman AJ, Nishimoto KP, Reddy A, Fairchild PJ.
Rapamycin conditioning of dendritic cells differentiated from human ES cells promotes a tolerogenic phenotype.
J Biomed Biotechnol. 2012;2012:172420.
doi: 10.1155/2012/172420.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
Mouse anti Human CD40 antibody, clone LOB7/6 (MCA1590) used to evaluate CD40 expression on canaine cells by flow cytometry.
Image caption:
Fig S2A: Among the PBMCs, a majority of the cells in the monocyte gate (60-70%) spontaneously expressed CD14, CD80, MHC II and CD40 at a high level but they did not express CD86
Fig S2B: After MACS selection, more than 90% of the cells were CD14+ and expressed CD80, MHC II and CD40 at a high level. Surprisingly approximately 30% of these cells also expressed CD86, suggesting that the positive selection process with the anti-CD14 antibody induced a cellular activation.
Fig 2C: After cMoDCs differentiation, the expression of CD14, CD80, MHC II and CD40 remained positive and high for a large majority of the cells (above 90%), while CD86 expression decreased under 10%.
From: Milhau N, Almouazen E, Bouteille S, Hellel-Bourtal I, Azzouz-Maache S, Benavides U, et al. (2020)
In vitro evaluations on canine monocyte-derived dendritic cells of a nanoparticles delivery system for vaccine antigen against Echinococcus granulosus.
PLoS ONE 15(2): e0229121.
doi: 10.1371/journal.pone.0229121
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
FITC conjugated Mouse anti Human CD40 antibody, clone LOB7/6 (MCA1590F) used to assess CD40 expression on CAL-1 cells by flow cytometry.
Image caption:
Phenotypic characterization of human CAL-1 cells and CCR7 induction upon exposure to GM-CSF and maturation by R848. (A) Surface expression of CD123, CD11c, CD40, CD86, HLA-DR and CCR7 (solid lines) on CAL-1 cells that were stimulated or not for 18-19h with the TLR9 ligand CpG-B ODN 2006 (1μM) or the TLR7/8 ligand Resiquimod R848 (10μg/ml). Representative flow cytometry histograms derived from one out of three independent experiments are depicted. Unstained cells or isotype-matched controls for CCR7 stainings are shown as dashed lines. (B) Surface expression of CD123, CD11c, CD40, CD86, HLA-DR and CCR7 on CAL-1 cells cultured for 3 days in the presence of 10ng/ml GM-CSF. Where indicated, these GM/CAL-1 cells were in addition matured by either CpG-B or R848 as in (A). Representative flow cytometry histograms derived from one out of three independent experiments are depicted. (C) Quantitative analysis of surface markers on CAL-1 (white bars) and GM/CAL-1 (blue bars) cells. Mean values ± SEM of the 3 independent experiments (A, B) are shown.
From: Uetz-von Allmen E, Samson GPB, Purvanov V, Maeda T, Legler DF.
CAL-1 as Cellular Model System to Study CCR7-Guided Human Dendritic Cell Migration.
Front Immunol. 2021 Sep 16;12:702453.
doi: 10.3389/fimmu.2021.702453.
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
Figure B. StarBright Violet 515 conjugated Mouse anti Human CD19 antibody, clone LT19 (MCA1940SBV515) and StarBright Blue 700 conjugated Mouse anti Human CD40 antibody, clone LOB7/6 (MCA1590SBB700).
All experiments performed on red cell lysed human blood gated on live single mononuclear cells, in the presence of 10% human serum. Data acquired on the ZE5 Cell Analyzer.
Figure B. StarBright Red 670 conjugated Mouse anti Human CD19 antibody, clone LT19 (MCA1940SBR670) and StarBright Violet 570 conjugated Rat anti Human CD40 antibody, clone LOB7/6 (MCA1590SBV570).
All experiments performed on red cell lysed human blood gated on live single lymphocytes, in the presence of 10% human serum. Data acquired on the ZE5 Cell analyser.
Figure B. StarBright Red 670 conjugated Mouse anti Human CD19 antibody, clone LT19 (MCA1940SBR670) and StarBright Violet 440 conjugated Mouse anti Human CD40 antibody, clone LOB7/6 (MCA1590SBV440). All experiments performed on red blood lysed human blood gated on live single cell granulocytes, in the presence of 10% human serum.
Data acquired on the ZE5 Cell analyser.
Figure B. StarBright UltraViolet 400 conjugated Mouse anti Human CD19 antibody, clone LT19 (MCA1940SBUV400) and StarBright Violet 610 conjugated Mouse anti Human CD40 antibody, clone LOB7/6 (MCA1590SBV610). All experiments performed on red blood lysed human blood gated on live single cell lymphocytes, in the presence of 10% human serum.
Data acquired on the ZE5 Cell analyser
Filter by Application:
E C IF F Reset| Mouse anti Human CD40 antibody, clone LOB7/6 recognizes the human CD40 cell surface antigen, a 48kDa glycoprotein expressed by B lymphocytes and weakly by some monocytes. CD40 is involved in the process of B cell selection in germinal centres and is vital in T cell-B cell interactions. |
- Target Species
- Human
- Species Cross-Reactivity
-
Target Species Cross Reactivity Dog - N.B. Antibody reactivity and working conditions may vary between species.
- Product Form
- Purified IgG conjugated to StarBright Violet 440 - liquid
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350
0.05% Tween 20 - Immunogen
- CD40 Ig(Fc) fusion protein containing the EC region of human CD40 and Fc region of human IgG.
- Approx. Protein Concentrations
- For information on the concentration of our StarBright Dye conjugated reagents please visit our FAQ page.
- Fusion Partners
- Spleen cells from immunised BALB/c mice were fused with cells of the mouse NS1 myeloma cell line.
- Max Ex/Em
-
Fluorophore Excitation Max (nm) Emission Max (nm) StarBright Violet 440 383 436 - Regulatory
- For research purposes only
- Guarantee
- 12 months from date of despatch
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
This product is shipped at ambient temperature.
Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted.
Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted.
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| Flow Cytometry 1 |  |
Neat |
- 1Staining at lower temperatures generally requires longer incubation to reach antibody binding equilibrium, and this effect is more pronounced for StarBright Dyes due to their larger size. For optimum staining, Bio-Rad recommends incubating samples either overnight at 4°C or 1 hour at room temperature.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Flow Cytometry
- Use 5μl of the suggested working dilution to label 0.5x106 cells in 100μl. Best practices suggest a 5 min centrifugation at 6,000g prior to sample application.
How to Use the Spectraviewer
Watch the Tool Tutorial Video ▸- Start by selecting the application you are interested in, with the option to select an instrument from the drop down menu or create a customized instrument
- Select the fluorophores or fluorescent proteins you want to include in your panel to check compatibility
- Select the lasers and filters you wish to include
- Select combined or multi-laser view to visualize the spectra
| Description | Product Code | Applications | Pack Size | List Price | Your Price | Quantity | |
|---|---|---|---|---|---|---|---|
| Human Seroblock | BUF070A | F | 50 Test | Log in | |||
| List Price | Your Price | ||||||
| Log in | |||||||
| Description | Human Seroblock | ||||||
| Human Seroblock | BUF070B | F | 200 Test | Log in | |||
| List Price | Your Price | ||||||
| Log in | |||||||
| Description | Human Seroblock | ||||||
References for CD40 antibody
-
Quadbeck, B. et al. (2002) Maturation of thyroidal dendritic cells in Graves' disease.
Scand J Immunol. 55 (6): 612-20. -
Kirsch, B. M. et al . (2005) The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function.
Arthritis Res. Ther. 7: R694-R703. -
Cheadle, E. et al. (2003) Mycobacterium bovis bacillus Calmette-Guerin-infected dendritic cells potently activate autologous T cells via a B7 and interleukin-12-dependent mechanism.
Immunology.108: 79-88. -
Carpenter, E.L. et al. (2009) Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.
J Transl Med. 7: 93. -
Garcia-Nieto, S. et al. (2010) Laminin and Fibronectin Treatment Leads to Generation of Dendritic Cells with Superior Endocytic Capacity.
PLoS ONE. 5: 1-10. -
Wang, Y.S. et al. (2007) Characterization of canine monocyte-derived dendritic cells with phenotypic and functional differentiation.
Can J Vet Res. 71: 165-74. -
Vlachoyiannopoulos, P.G. et al. (2004) Anti-CD40 antibodies in antiphospholipid syndrome and systemic lupus erythematosus.
Thromb Haemost. 92: 1303-11. -
Leigh, J.E. et al. (2006) Characterization of the immune status of CD8+ T cells in oral lesions of human immunodeficiency virus-infected persons with oropharyngeal Candidiasis.
Clin Vaccine Immunol. 13: 678-83.
View The Latest Product References
-
Newman, K.C. et al. (2006) Cross-talk with myeloid accessory cells regulates human natural killer cell interferon-gamma responses to malaria.
PLoS Pathog. 2: e118. -
Kuijf, M.L. et al. (2010) TLR4-mediated sensing of Campylobacter jejuni by dendritic cells is determined by sialylation.
J Immunol. 185: 748-55. -
Huizinga R et al. (2015) Innate Immunity to Campylobacter jejuni in Guillain-Barré Syndrome.
Ann Neurol. 78 (3): 343-54. -
Yıldırım C et al. (2015) Galectin-2 induces a proinflammatory, anti-arteriogenic phenotype in monocytes and macrophages.
PLoS One. 10 (4): e0124347. -
Brencicova, E. et al. (2017) Interleukin-10 and prostaglandin E2 have complementary but distinct suppressive effects on Toll-like receptor-mediated dendritic cell activation in ovarian carcinoma.
PLoS One. 12 (4): e0175712. -
Silk, K.M. et al. (2012) Rapamycin conditioning of dendritic cells differentiated from human ES cells promotes a tolerogenic phenotype.
J Biomed Biotechnol. 2012: 172420. -
Tischer, S. et al. (2011) Heat shock protein 70/peptide complexes: potent mediators for the generation of antiviral T cells particularly with regard to low precursor frequencies.
J Transl Med. 9: 175. -
Unosson, J. et al. (2021) Acute cardiovascular effects of controlled exposure to dilute Petrodiesel and biodiesel exhaust in healthy volunteers: a crossover study.
Part Fibre Toxicol. 18 (1): 22. -
Milhau, N. et al. (2020) In vitro. evaluations on canine monocyte-derived dendritic cells of a nanoparticles delivery system for vaccine antigen against Echinococcus granulosus..
PLoS One. 15 (2): e0229121. -
Uetz-von Allmen, E et al. (2021) CAL-1 as Cellular Model System to Study CCR7-Guided Human Dendritic Cell Migration.
Front Immunol. 12: 702453.
- UniProt
- P25942
- Entrez Gene
- CD40
- GO Terms
- GO:0005576 extracellular region
- GO:0004872 receptor activity
- GO:0006461 protein complex assembly
- GO:0006954 inflammatory response
- GO:0009898 internal side of plasma membrane
- GO:0019899 enzyme binding
- GO:0030168 platelet activation
- GO:0035631 CD40 receptor complex
- GO:0042100 B cell proliferation
- View More GO Terms
- GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB cascade
MCA1590SBV440
64575922
If you cannot find the batch/lot you are looking for please contact our technical support team for assistance.
View more products with CD40 specificity
Please Note: All Products are "FOR RESEARCH PURPOSES ONLY"
View all Anti-Human ProductsAlways be the first to know.
When we launch new products and resources to help you achieve more in the lab.
Yes, sign me up
